Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors

Cancer Cell(2022)10.1016/j.ccell.2022.04.006Source: DataRank Database

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors is a research paper published in Cancer Cell (2022). On theSindex it has a DataRank of 0.655. It has been cited 78 times.

N/A

0.655DataRank · unranked

Scored on demand from live citation data

Open Access78 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 6.51)OA: greenTopics (42)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.655

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (4)

Zhaohua Hou ORCID,Alfredo Amador-Molina ORCID,Prasad S. Adusumilli ORCID,Leonid Cherkassky

Live enrichment

PubMed:35487216 PMC:PMC9197990 OpenAlex:https://openalex.org/W4225247905

National Institutes of Health

Grant: P30 CA008748

National Institutes of Health

Grant: R01 CA235667

National Institutes of Health

Grant: R01 CA236615-01

U.S. Department of Defense

Grant: BC132124

U.S. Department of Defense

Grant: CA170630

U.S. Department of Defense

Grant: CA180889

U.S. Department of Defense

Grant: CA200437

U.S. Department of Defense

Grant: LC160212

NCI NIH HHS

Grant: R01 CA236615

National Institutes of Health

Grant: 5R01CA235667-02

A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma

National Institutes of Health

Grant: 5R01CA236615-02

Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

Commonwealth Foundation for Cancer Research Foundation

Derfner Foundation

Atara Biotherapeutics

Geoffrey Beene Foundation

FWCI

6.51

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier Non-Commercial

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9197990

publisherhttps://api.elsevier.com/content/article/PII:S1535610822001684?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610822001684?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2022.04.006

Fields of Study

CAR-T cell therapy researchNanowire Synthesis and ApplicationsAdvancements in Semiconductor Devices and Circuit Design0301 basic medicine03 medical and health sciences0302 clinical medicineAntigens, NeoplasmHumansImmunotherapy, AdoptiveNeoplasmsReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesTumor Microenvironment

MeSH Terms

Receptors, Chimeric AntigenAntigens, NeoplasmHumansNeoplasmsReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveTumor Microenvironment

Keywords

Chimeric antigen receptorInfiltration (HVAC)Cancer researchImmunityImmunotherapyMedicineImmunologyImmune systemAdoptive Cell TherapyRegional TherapiesChimeric Antigen Receptor (Car) T cellsSolid Tumors Cell TherapyReceptors, Chimeric AntigenAntigens, NeoplasmNeoplasmsT-LymphocytesReceptors, Antigen, T-CellTumor MicroenvironmentHumansImmunotherapy, Adoptive

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708420.v1figshare

Additional file 1 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708420figshare

Additional file 2 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708423.v1figshare

Additional file 2 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708423figshare

Additional file 3 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708426.v1figshare

Additional file 3 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708426figshare

Additional file 4 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708429.v1figshare

Additional file 4 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708429figshare

Additional file 5 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708432.v1figshare

Additional file 5 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708432figshare

Additional file 6 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708435.v1figshare

Additional file 6 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708435figshare

Additional file 7 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708438.v1figshare

Additional file 7 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708438figshare

Additional file 8 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708441.v1figshare

Additional file 8 of Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer

10.6084/m9.figshare.26708441figshare

Related Papers (9)

High-performance multiplex drug-gated CAR circuits

N/A

0.697DataRank · unranked

Cancer Cell(2022)

co-citedsame journal

10.1016/j.ccell.2022.08.008

Precise T cell recognition programs designed by transcriptionally linking multiple receptors

Science(2020)

co-cited

10.1126/science.abc6270

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

N/A

0.934DataRank · unranked

Science Translational Medicine(2021)

co-cited

10.1126/scitranslmed.abe7378

Delivery technologies for T cell gene editing: Applications in cancer immunotherapy

N/A

0.694DataRank · unranked

EBioMedicine(2021)

co-cited

10.1016/j.ebiom.2021.103354

Synthetic cytokine circuits that drive T cells into immune-excluded tumors

Science(2022)

co-cited

10.1126/science.aba1624

EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity

Cell stem cell(2022)

co-cited

10.1016/j.stem.2022.06.014

Probiotic-guided CAR-T cells for solid tumor targeting

Science(2023)

co-cited

10.1126/science.add7034

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

N/A

0.816DataRank · unranked

Nature Communications(2023)

co-cited

10.1038/s41467-023-40850-5

Synapse-tuned CARs enhance immune cell anti-tumor activity

N/A

2.1DataRank · unranked

Nature Biotechnology(2023)

co-cited

10.1038/s41587-022-01650-2

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors

FAIR Checklist

DataRank Breakdown

Authors (4)

Funding (16 grants)

Impact

Open Access

Topics

Linked Datasets (16)

Annotations (Europe PMC)

Related Papers (9)